Pill Identifier App

Label Changes for:

Venlafaxine Extended Release Tablets

December 2012

Changes have been made to the CONTRAINDICATIONS, WARNINGS and PRECAUTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – December 2012

 

CONTRAINDICATIONS

Monoamine Oxidase Inhibitors (MAOIs)
  • The use of MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets is contraindicated because of an increased risk of serotonin syndrome…
 
Hide
(web3)